Exposure to factor VIII and prediction of inhibitor development: exposure days vs. danger days, or both?-Reference-Cited by-同舟云学术

Exposure to factor VIII and prediction of inhibitor development: exposure days vs. danger days, or both?

Published:2012-10 Issue:10 Volume:10 Page:2194-2196
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:

Author:

HERMANS C.,ASTERMARK J.,DE MOERLOOSE P.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1538-7836.2012.04871.x/fullpdf

Reference17 articles.

1. Epidemiology of Inhibitors

2. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom;Hay;Blood,2011

3. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group;Lusher;N Engl J Med,1993

4. The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors;McMillan;Blood,1988

5. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group;Bray;Blood,1994

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A post hoc analysis of previously untreated patients with severe hemophilia A who developed inhibitors in the PUPs A-LONG trial;Blood Advances;2024-03-15

2. Mutation detection and inhibitor analysis of 43 children with severe hemophilia A in a single center: three novel mutations;Indian Journal of Hematology and Blood Transfusion;2023-07-24

3. Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A;Molecular Therapy;2021-02

4. Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A;Clinical and Applied Thrombosis/Hemostasis;2021-01-01

5. Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A;Thrombosis and Haemostasis;2020-07-27